ASH: Daratumumab Beneficial for Patients With Multiple Myeloma
WEDNESDAY, Dec. 13, 2023 -- For transplantation-eligible patients with newly diagnosed multiple myeloma, the addition of subcutaneous daratumumab combined with bortezomib, lenalidomide, and dexamethasone induction and consolidation therapy and with... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 13, 2023 Category: Pharmaceuticals Source Type: news
'Half-Matched' BMTs Effective in Severe Sickle Cell Disease
(MedPage Today) -- SAN DIEGO -- A reduced-intensity "half-matched" bone marrow transplant (BMT) protocol demonstrated durable donor engraftment, with encouraging survival rates, in adults with severe sickle cell disease (SCD) for whom stem cell... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 13, 2023 Category: Hematology Source Type: news
Dengue Fever Is Soaring Worldwide. Here ’s What to Know—and How to Stay Protected
Governments and public health experts around the world are sounding the alarm about the record-high spread of one of the most notorious—and incurable—diseases, which about half the world is at risk of catching: dengue.
The mosquito-borne virus has a long history in warm climates but is now also emerging in regions where it had been generally unheard of—such as in Europe and parts of the U.S. By early December, there had already been more than five million dengue infections worldwide this year—a dramatic increase from some 500,000 cases in 2000—recorded across at least 80 countries and terri...
Source: TIME: Health - December 13, 2023 Category: Consumer Health News Authors: Koh Ewe Tags: Uncategorized Explainer News Desk Source Type: news
MRD Status Predicts Transplant Benefit in NPM1-Mutated AML MRD Status Predicts Transplant Benefit in NPM1-Mutated AML
MRD-positive patients in first complete remission after induction therapy had a survival benefit after transplant; however, that benefit did not extend to MRD-negative patients after transplant.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - December 12, 2023 Category: Cancer & Oncology Tags: Hematology-Oncology Source Type: news
MRD Tied to Allo-Transplant Benefit in NPM1-Mutated Acute Myeloid Leukemia
(MedPage Today) -- SAN DIEGO -- Measurable residual disease (MRD) after induction therapy can guide the use of allogeneic transplant in patients with NPM1-mutated acute myeloid leukemia (AML) in first remission, regardless of whether FLT3 internal... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 11, 2023 Category: Hematology Source Type: news
Medscape Now! Hot Topics in Women ’s Health December 2023 Medscape Now! Hot Topics in Women ’s Health December 2023
Find out about how gender impacts outcomes in PTSD and cardiogenic shock.Medscape Education Clinical Briefs (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - December 11, 2023 Category: Transplant Surgery Tags: Ob/Gyn & Women ' s Health Clinical Brief Source Type: news
New data for Roche ’s Columvi and Lunsumio presented at ASH 2023 support continued benefit for people with lymphoma
Longer-term data from pivotal studies of fixed-duration Columvi and Lunsumio continue to show durable responses in people with heavily pre-treated lymphomas1,2New data reinforce the potential of combination regimens in earlier treatment settings and add to the robust body of evidence supporting ongoing Phase III studies3,4,5,6Basel, 11 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its CD20xCD3 T-cell engaging bispecific antibody programme, including eight oral presentations, were presented at the 65th American Society of Hematology (ASH) Annual Meeting& Exposition, 9-12 December ...
Source: Roche Media News - December 11, 2023 Category: Pharmaceuticals Source Type: news
New data for Roche ’s Columvi and Lunsumio presented at ASH 2023 support continued benefit for people with lymphoma
Longer-term data from pivotal studies of fixed-duration Columvi and Lunsumio continue to show durable responses in people with heavily pre-treated lymphomas1,2New data reinforce the potential of combination regimens in earlier treatment settings and add to the robust body of evidence supporting ongoing Phase III studies3,4,5,6Basel, 11 December 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that new data from its CD20xCD3 T-cell engaging bispecific antibody programme, including eight oral presentations, were presented at the 65th American Society of Hematology (ASH) Annual Meeting& Exposition, 9-12 December ...
Source: Roche Investor Update - December 11, 2023 Category: Pharmaceuticals Source Type: news
Tampa General Hospital to break ground on 13-story expansion in 2024
The hospital's plan to build the TGH Surgical, Neuroscience and Transplant Pavilion on its Davis Islands campus has received unanimous approval from Tampa City Council. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - December 11, 2023 Category: Pharmaceuticals Authors: Ashley Gurbal Kritzer Source Type: news
ASCT Tops CAR T-Cell Therapy for Relapsed LBCL in Complete Remission
(MedPage Today) -- SAN DIEGO -- Autologous stem-cell transplantation (ASCT) led to improved outcomes as compared with CAR T-cell therapy for patients with relapsed large B-cell lymphoma (LBCL) in complete remission, a retrospective analysis showed... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - December 11, 2023 Category: Hematology Source Type: news
Sickle Cell Gene Therapy'Truly Transformative'Sickle Cell Gene Therapy'Truly Transformative '
Patients who received lovo-cel had durable remissions and reductions in vaso-occlusive events, pain crises, and hospitalizations in the longest running gene therapy trial for sickle cell disease.Medscape Medical News (Source: Medscape Transplantation Headlines)
Source: Medscape Transplantation Headlines - December 10, 2023 Category: Transplant Surgery Tags: Hematology-Oncology Source Type: news
Thousands of kidney disease patients set to benefit from £1-a-dose diabetes drug which can reduce the need for dialysis and a transplant
Kidney disease is usually triggered by the damage caused by another illness, such as type 1 and type 2 diabetes or high blood pressure. (Source: the Mail online | Health)
Source: the Mail online | Health - December 9, 2023 Category: Consumer Health News Source Type: news
New Sickle Cell Therapies Will Be Out of Reach Where They Are Needed Most
Nasra Gwoto, 10, and her brother, Ramadhani, 12, traveled with their mother from Tanzania to India to get a bone-marrow transplant for sickle cell disease. The procedure is risky, and their mother wishes they could have received a new gene therapy instead. There is no clear path for African…#nasragwoto #tanzania #african #lyfgenia #bluebirdbio #vertex #saudiarabia #africa #whatsapp #shanimgaraganza (Source: Reuters: Health)
Source: Reuters: Health - December 9, 2023 Category: Consumer Health News Source Type: news
New Sickle Cell Therapies Will Be Out of Reach Where They Are Needed Most
There is no clear path for African patients to get access to the treatments, which have multimillion-dollar price tags and are highly complex to manufacture and deliver. (Source: NYT Health)
Source: NYT Health - December 8, 2023 Category: Consumer Health News Authors: Rebecca Robbins and Stephanie Nolen Tags: Sickle Cell Anemia Genetic Engineering Blood Genetics and Heredity Income Inequality Bone Marrow Drugs (Pharmaceuticals) Therapy and Rehabilitation Developing Countries Crispr (DNA) Transplants Stem Cells Food and Drug Administrati Source Type: news
